Travere Therapeutics, Inc.
TVTX
Classificação em ações
#3424
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Preço da ação
$52.95
Última sincronização: 2026-10-21
Valor de mercado
$4.99B
Variação (1 dia)
1.24%
Variação (1 ano)
92.69%
País
US
Negociar Travere Therapeutics, Inc. (TVTX)
Categoria
Healthcare
Histórico de preços das ações de Travere Therapeutics, Inc. (TVTX)
Preço de fecho mais alto: $53.35 em 2026-10-01
Preço de fecho mais baixo: $1.88 em 2012-11-01
Preço de fecho mais baixo: $1.88 em 2012-11-01
Histórico de preços das ações da Travere Therapeutics, Inc. de 2012 a 2026
Desempenho anual do preço das ações
| Ano | Desempenho |
|---|---|
| 2026 (TTM) | 21.63% |
| 2025 | 98.56% |
| 2024 | 113.02% |
| 2023 | -57.16% |
| 2022 | -32.13% |
| 2021 | 10.99% |
| 2020 | 87.35% |
| 2019 | -40.02% |
| 2018 | 7.59% |
| 2017 | 9.33% |
| 2016 | -3.75% |
| 2015 | 81.19% |
| 2014 | 54.72% |
| 2013 | 74.64% |
| 2012 | 0.00% |
Preço das ações de empresas similares ou concorrentes
| Empresa | Preço da ação | Variação 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
